The primary therapeutic role of Caramelos Multibióticos is to provide focused, dual-action supportive relief for symptoms related to physical discomfort localized to the oropharyngeal cavity and mouth. The lozenge is intended for the symptomatic relief of pain and discomfort associated with inflammatory or irritative states.

The lozenge is commonly used for managing symptoms related to physical discomfort, including sore throat, painful swallowing, and discomfort associated with throat and mouth irritative states.

“The symptomatic relief provided may assist with maintaining functional stability and supports general well-being during symptomatic phases.”

The medication is relevant in contexts where short-term symptomatic assistance is needed during episodes of acute throat and mouth irritation. The focused symptomatic relief helps address symptoms that interfere with daily functioning, and the antiseptic agent contributes to easing the overall symptom load by supporting localized management of irritative states.

---

Quick Fact: Relief for Acute Pain & Irritation

The lozenge is commonly used across conditions presenting with acute episodes of localized pain and is considered relevant when supportive symptom management is appropriate for discomfort in the throat and mouth.

Regulatory References

1. HPRA Summary of Product Characteristics

Who can and cannot use Caramelos Multibióticos?

The eligibility for Caramelos Multibióticos (Benzocaine/Dequalinium Chloride lozenge) is defined by official regulatory documents, strictly limiting its use to specific populations. The medicine is generally indicated for Adults and Adolescents, with minimum age requirements varying between 12 years and 16 years depending on the specific product label.

Use is absolutely contraindicated in several populations. This includes Infants and Children younger than 2 years due to the serious risk of methemoglobinemia associated with the Benzocaine component. It is also prohibited for individuals with a history of or suspected methemoglobinemia, known hypersensitivity to the active ingredients or related ester-type anesthetics, and those with low plasma cholinesterase concentrations.

Furthermore, the lozenge is not recommended for use during pregnancy or lactation due to insufficient data to establish safety status in these populations. Special caution is warranted for patients with aspiration or swallowing problems, Myasthenia Gravis, or pre-existing conditions, like heart disease, that increase the risk of methemoglobinemia.

Interactions with Other Medicines and Products

The formulation of Caramelos Multibióticos often includes local anesthetic and antimicrobial agents, such as benzocaine and tyrothricin, which have distinct interaction profiles, particularly due to the presence of benzocaine.

Pharmacodynamic Interactions

Benzocaine, a local anesthetic, can increase the risk of developing methemoglobinemia when used concurrently with other medicines or substances known to induce this condition. These potentially interacting products may include, but are not limited to, acetaminophen, certain nitrates and nitrites (such as nitroglycerin and nitric oxide), procaine, chloroquine, and other local anesthetics like lidocaine or prilocaine. The concurrent use of these agents may lead to an additive increase in the body's capacity to form methemoglobin, reducing the blood's oxygen-carrying capacity. Close monitoring is essential when these combinations are used.

Drug Class Interactions

As the lozenge contains antimicrobial components (e.g., tyrothricin, or potentially a probiotic), there is a theoretical potential for interaction with systemic antibiotics. The efficacy of systemic antibiotics may be affected by the use of local antimicrobials. Furthermore, in formulations containing probiotics, caution is generally advised with concomitant use of immunosuppressants, as this combination may theoretically increase the risk of infection. The clinical relevance of these local interactions with minimal systemic absorption is generally considered low, but awareness of the potential for additive effects or antagonistic action is important for patient safety.

Caramelos Multibióticos is a fixed-dose combination containing dequalinium chloride and benzocaine, targeting microbial proliferation and somatosensory nerve impulse transmission in the oropharyngeal mucosa.

Dequalinium chloride, a bis-quaternary ammonium compound, operates as a cationic surfactant. Its primary biological target is the microbial cell, where it preferentially binds to and disrupts the integrity of the cell membrane lipid bilayer. This physical disruption induces cellular permeability, leading to the leakage of intracellular contents and subsequent cell lysis. Furthermore, dequalinium chloride accumulates within microbial mitochondria, inhibiting F1-ATPase and key enzymes in the respiratory chain and glycolysis, resulting in the depletion of cellular ATP.

Benzocaine, an ester-class local anesthetic, acts on voltage-gated sodium channels (VGSCs) located in the neuronal membranes of sensory afferent fibers. It functions as a channel blocker, diffusing into the neuron in its non-ionized state and subsequently binding to the alpha subunit of the VGSC in its ionized form. This interaction inhibits channel opening, which prevents the influx of sodium ions (Na^+) required for cell depolarization. The consequence is a localized stabilization of the neuronal membrane and a blockade of action potential initiation and propagation, thereby interrupting signal conduction to the central nervous system.

How to use Caramelos Multibióticos: Administration and Usage

Administration Scope The medicine is intended for the oromucosal route, where it is applied topically to the mucous membrane of the mouth and throat. This is achieved using the hard lozenge form, which contains the combination of Benzocaine (10 mg) and Dequalinium Chloride (0.25 mg).

Aspect	Description
Unit Dose & Limit	The unit dose is one lozenge. The total daily administration does not exceed eight lozenges in a 24-hour period.
Frequency Pattern	Administration is typically intermittent, with one lozenge used every two hours (q2h) as required, while remaining within the 24-hour maximum limit.
Administration Technique	The lozenge is allowed to dissolve slowly in the mouth to facilitate the local action of the active ingredients; it is not meant to be chewed or swallowed whole.
Age-Group Rule	The standard use is for adults and adolescents aged 12 years and older. Use is not recommended for children under 12 years of age.

Use Protocol The overall usage pattern is characterized as short-term symptomatic assistance. This involves the technique of slow oral dissolution and the observance of the two-hour minimum interval between doses. This model for topical application manages the total daily dose, ensuring the medicine is used within established parameters for the combination product.

Caramelos Multibióticos: Recent Clinical Evidence

Evidence for Symptomatic Relief of Minor Oral and Throat Discomfort

Research exploring the effects of lozenges containing local anesthetic agents, such as Benzocaine, has been primarily conducted using randomized controlled trials (RCTs). These studies were evaluated in research exploring how the lozenge's components were studied for the symptomatic relief of acute, localized pain and discomfort in the throat and mouth. The trials were applied in studies examining patient-reported outcomes describing perceived discomfort related to acute symptom activity, such as those associated with uncomplicated sore throat.

Focus of Clinical Trials: Onset and Degree of Pain Relief

Clinical trials often examine how quickly the local anesthetic component is observed in research. Studies monitored the time it took for the participants to perceive a change in symptoms, and they researched short-term symptom changes by measuring the intensity or variability of symptoms using standardized pain scales. Research provides insight into short-term changes with studies reporting patterns observed in the research, particularly concerning symptom change during the initial hours after administration. These outcomes related to physical discomfort was observed in some studies over defined time intervals.

Research on Dual Action: Anesthetic and Antiseptic Components

The overall evidence landscape for this combination lozenge was evaluated in studies looking at its two main components. The analgesic action (Benzocaine) was studied in clinical settings, as described above. The antiseptic component, Dequalinium Chloride, was studied for its wide range of antimicrobial action. This antiseptic action is primarily supported by in vitro laboratory studies which are used in research contexts involving surface microbial management. These findings describe patterns observed in the laboratory but do not directly reflect clinical outcomes in the patient.

---

Study Duration and Long-Term Follow-up

The available research focuses predominantly on outcomes describing episodic or acute changes associated with sore throats. Short-term efficacy of the anesthetic component was evaluated in single-dose trials, where follow-up durations were limited to the initial two to three hours after participants received the lozenge. For multi-dose use, studies explored symptom patterns and their evolution over intermediate time periods, generally lasting three to five days. There is limited information for long-term outcomes, as the research is primarily designed to assess the medicine's role during the acute phase where symptoms may become more noticeable.

---

Evidence in Specific Populations

The clinical evidence for these lozenges was observed in trials that predominantly included adults (typically ge 18 years of age) presenting with moderate-to-severe acute throat discomfort. Data for certain groups remain insufficient, as dedicated clinical research is not widely available for populations such as children or older adults. Therefore, results apply only to the populations studied in the primary clinical trials.

---

What is Still Uncertain About the Research Evidence

While studies contribute to the broader evidence landscape for local anesthetic lozenges, several limitations and areas of uncertainty remain. Comparative evidence is lacking for the specific combination of Benzocaine and Dequalinium Chloride against a true placebo; much of the evidence is derived from component studies. Furthermore, the findings are mostly concentrated on the pain relief component. Research that quantifies the added impact of the antiseptic agent on the overall course of symptoms remains limited, and its primary support comes from laboratory settings. Evidence quality varies across studies, and existing research provides limited insight into long-term or durable outcomes related to systemic or functional imbalance after the acute symptom phase.

Key Studies & References Summary of Product Characteristics (SPC) for Dequalinium Chloride / Benzocaine Lozenges (HPRA)

Common questions about Caramelos Multibióticos (FAQ)

Q: What is the main purpose of Caramelos Multibióticos as described in the official documents?

According to official product information, the main purpose of this medicine is for the local symptomatic relief of discomfort in the mouth and throat. This includes addressing symptoms such as sore throat pain and irritation.

---

Q: What does the term 'Multibióticos' refer to in this specific product?

The regulatory documents define the active ingredients in this lozenge. These are Dequalinium Chloride, which is an antimicrobial agent, and Benzocaine, which is described as a local anesthetic for the symptomatic relief of pain.

---

Q: What distinguishes Caramelos Multibióticos from a simple sugary candy?

This product is classified as a medicine because it contains active pharmaceutical ingredients (APIs). These ingredients are designed to provide a recognized therapeutic action, consistent with its classification as a medicine.

---

Q: Is this product classified as a drug, a supplement, or a medical device?

Official regulatory documents classify Caramelos Multibióticos as a medicine or drug. This means it contains specific active pharmaceutical ingredients and is subject to government regulatory oversight.

---

Q: Can a temporary change in bowel habits be a common expectation after starting this product?

The side effects listed in official documents generally pertain to the area of application, which is the mouth and throat. These often include localized effects such as irritation or tingling in the mouth. Systemic changes like temporary changes in bowel habits are not listed in the documentation as a direct side effect of this local treatment.

---

Q: What non-serious side effects are listed in the official patient information?

Official patient information lists adverse effects that can occur with the use of the product. These include localized symptoms like irritation, mouth tingling, or burning. Skin reactions such as a rash, pruritus (itching), or contact dermatitis have also been noted.

---

Q: Is there any information about the potential for allergic reactions to the ingredients?

Regulatory warnings state that hypersensitivity (allergic reaction) to the active ingredients is a contraindication. Severe warnings include symptoms such as a rash, hives, or swelling, which are indications of an allergic reaction.

---

Q: Is it typical to experience mild digestive discomfort like gas or bloating?

Mild digestive discomfort such as gas or bloating is not commonly listed as a direct side effect in official patient information. Most listed adverse effects relate specifically to the area of application (mouth and throat).

---

Q: Does the official labeling mention any major food or drink interactions?

The official labeling does not specifically list food or drink interactions. However, due to the anesthetic effects of Benzocaine, it is advised to avoid consuming food or drinks for a period immediately following use to prevent accidentally biting the numb area or choking.

---

Q: Is it recommended to avoid eating or drinking immediately after dissolving the lozenge?

Yes, regulatory guidance recommends avoiding food and drink for at least one hour after using the lozenge. This measure helps prevent accidental injury or choking that could result from the temporary numbing effect in the mouth and throat.

---

Q: What is the recommended time difference for taking this alongside a prescription oral antibiotic?

The official documentation notes a potential interaction where the Benzocaine component can produce PABA, which may antagonize the effects of sulphonamides, a class of antibiotics. Official product information does not define a specific time difference for spacing these two types of medicines.

---

Q: Are there specific warnings for use during pregnancy, according to the official labeling?

Regulatory documents for the combination product recommend not taking Caramelos Multibióticos during pregnancy. This is because the safety of the product's use during pregnancy has not been established through appropriate studies.

---

Q: Are there restrictions on use for individuals who are currently breastfeeding?

Official product information recommends not taking the product while breastfeeding. This guidance is in place because the safety of the product's use for the infant while breastfeeding has not been established.

---

Q: Who are the groups of people who should avoid using this product according to official warnings?

Official warnings state that the product is contraindicated for people with hypersensitivity to any of its components. Specific groups to avoid use include those taking certain medicines like anticholinesterases, or individuals with certain rare hereditary sugar problems such as fructose intolerance.

---

Q: Is the product listed as suitable for people with diabetes or other blood sugar concerns?

Regulatory information suggests that individuals with high blood sugar concerns, such as diabetes, should verify the label content closely for inactive ingredients. This is because lozenge products commonly contain sugar or glucose as part of their formulation, which may be relevant to dietary management.

---

Q: What is the typical timeframe for users to notice the described effects?

The local anesthetic component is observed to provide an effect shortly after administration. Clinical findings suggest that the median time to worthwhile pain relief was reported as 20 minutes.

---

Q: How long is the duration of action for the lozenge's local effects?

Clinical findings suggest that the local anesthetic component has an observed duration of action of approximately 10 minutes following application to the affected area.

---

Q: What are the circumstances under which official documentation suggests stopping use?

Official documentation states that product use is not recommended when symptoms are severe or persist longer than 2 days. Use should also be discontinued if symptoms occur along with fever, headache, rash, swelling, nausea, or vomiting.

---

Q: What inactive ingredients (e.g., sweeteners, flavorings) are used in Caramelos Multibióticos?

While official documentation specifies the active ingredients, the full list of inactive ingredients varies by product. Similar lozenge products may contain excipients such as icing sugar, liquid glucose, citric acid, sodium saccharin, and various flavorings to give the product its taste and form.

---

Q: Do the official instructions provide specific storage recommendations (e.g., temperature/light)?

Regulatory documents include specific guidance on storage. The product should generally not be stored above 25 C or 30 C, depending on the specific formulation. It is also advised to keep the medicine out of the reach of children.

---

Q: Is it safe to use the product after the expiration date printed on the packaging?

The official documentation defines the shelf life, which is typically around 3 years from the manufacturing date. Official regulatory information provides no guidance regarding the safety or effectiveness of using the product after the expiration date printed on the packaging.

---

Q: Does the official documentation specify the bacterial strains or active components used?

The official documentation lists the active components in the product as Benzocaine and Dequalinium Chloride. The documentation does not, however, specify any particular bacterial strains.

---

Q: Are there concerns about children mistaking the product for regular candy?

Regulatory warnings state that the medicine should be stored out of the reach of children due to potential safety risks associated with accidental ingestion. This is a general safety rule for all medicines, particularly those with a candy-like appearance.

---

Q: What are the listed components that may cause issues for people with specific allergies (e.g., gluten, lactose)?

The product is strictly contraindicated for people with hypersensitivity to any of its components. While excipients like gluten or lactose are not always listed in summaries, official patient leaflets should be consulted for the full list of ingredients to verify specific allergies.

---

Q: How should Caramelos Multibióticos be stored to maintain its effectiveness?

To maintain its effectiveness, the product should be stored in a dry place below 25 C or 30 C, as specified in the official instructions. It must also be protected as directed by the packaging.

---

Q: Does the product contain any traditional or prescription antibiotic medication?

The medicine contains Dequalinium Chloride, which is classified as an antimicrobial agent, with effects against microbial cell structures. The documentation does not classify this ingredient as a traditional or prescription antibiotic medication.

---

Q: Why is the product in a lozenge format instead of a traditional capsule or liquid?

The product is in a lozenge format because this is required to ensure the medicine is administered via the oromucosal route. This delivery method allows the active ingredients to provide their intended local action directly to the mouth and throat.

---

Q: What is the recommended maximum duration of continuous use of the product?

Official guidelines specify that the lozenges are intended for use of no more than 2 days continuously. Use beyond this timeframe is not addressed in standard regulatory guidance.

Official Storage and Disposal Requirements

Storage of Caramelos Multibióticos (Benzocaine/Dequalinium Chloride lozenges) is governed by specific regulatory requirements to ensure product stability and safety.

Storage Conditions: The medicine must be stored at or below the maximum temperature specified on the label, typically 25 C or 30 C. Lozenge stability requires storage in a dry place and protection from light and excessive moisture. The medicine should be kept in its original container throughout its labeled shelf life.

Child Safety: All official labeling mandates that the product be stored out of the sight and reach of children.

Disposal: Unused or expired lozenges must be disposed of in accordance with local requirements. Regulatory documents instruct that the product should not be disposed of via household wastewater or common trash, preventing environmental contamination.